Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Pluristem Therapeutics, Inc. (OTC: PSTI).

Full DD Report for PSTI

You must become a subscriber to view this report.


Recent News from (OTC: PSTI)

Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights
HAIFA, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today reported financial results and corporate developments for its third quarter of fiscal 2018 ended March 31, 2018. &#x...
Source: GlobeNewswire
Date: May, 10 2018 07:00
Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay
Karyopharm (KPTI) slumped 17% in the pre-market yesterday, ahead of data from a mid stage study of selinexor in treatment-resistant multiple myeloma. A couple of years ago, this same drug was pitted against Darzalex in the same indication and showed similar efficacy. An FDA filing was planned ...
Source: SeekingAlpha
Date: May, 02 2018 08:00
3 Things In Biotech, May 1: Merck's Horizons, Pluristem's Nod, Reg/San Look To Break In
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a...
Source: SeekingAlpha
Date: May, 02 2018 08:00
Pluristem up 15% on FDA clearance of PLX-R18 for acute radiation exposure
Thinly traded micro cap Pluristem Therapeutics ( PSTI +14.5% ) is up on a 6x surge in volume on the heels of the FDA's approval of its IND for cell therapy PLX-R18 for the treatment of acute radiation syndrome. More news on: Pluristem Therapeutics, Inc., Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: April, 30 2018 10:08
Premarket Gainers as of 9:05 am (04/30/2018)
STDY +81%  on acquisition by United Therapeutics for up to $216M. More news on: SteadyMed, Pluristem Therapeutics, Inc., Andeavor, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 30 2018 09:27
U.S. FDA Clears Pluristem's IND to Treat Victims Exposed to Acute Radiation
HAIFA, Israel, April 30, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug ...
Source: GlobeNewswire
Date: April, 30 2018 07:00
Your Daily Pharma Scoop: Takeda Acquisitions, Concert Trial Update, Sangamo Offering
Analysis focus: Takeda As I was telling Brian Bain of DIY Investing yesterday in an interview (a part of their DIY Summit - see here ), there’s a lot of talk going on about repatriated American tax dollars set to start a boom in M&A. However, quietly in the background, these ...
Source: SeekingAlpha
Date: April, 26 2018 08:00
Premarket Gainers as of 9:05 am (04/25/2018)
CHEK +21% . More news on: Check-Cap Ltd., Oragenics, Inc., Scorpio Tankers Inc., , Read more ...
Source: SeekingAlpha
Date: April, 25 2018 09:13
FDA on board with Pluristem's late-stage study of PLX-PAD for muscle injury following hip fracture surgery; shares up 6% premarket
Thinly traded micro cap Pluristem Therapeutics (NASDAQ: PSTI ) is up  6%  premarket on light volume in response to its announcement that the FDA has signed off on a Phase 3 clinical trial assessing its PLX-PAD cell therapy for the treatment of muscle injury following surgical rep...
Source: SeekingAlpha
Date: April, 25 2018 07:27
U.S. FDA Clears Pluristem's Phase III Study in Treatment of Muscle Injury Following Hip Fracture Surgery
HAIFA, Israel, April 25, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced today that the U.S. Food and Drug Administration (FDA) has cleared Pluristem’s Investigational Drug Applic...
Source: GlobeNewswire
Date: April, 25 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-141.231.271.271.23312,168
2018-08-131.231.241.261.23214,392
2018-08-101.251.2551.271.2345144,089
2018-08-091.241.251.251.2301108,313
2018-08-081.241.241.251.2378,931

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report. Get a complete short report on PSTI.


About Pluristem Therapeutics, Inc. (OTC: PSTI)

Logo for Pluristem Therapeutics, Inc. (OTC: PSTI)

Not available

 

Contact Information

 

 

Current Management

  • Menachem Mendi Ze evi / CEO
  • Yaky Yanay / President, COO
  • Boaz GurLavie / CFO, Secretary

Current Share Structure

  • Market Cap: $161,842,718 - 03/21/2018
  • Issue and Outstanding: 110,097,087 - 02/01/2018

 


Recent Filings from (OTC: PSTI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 03 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: February, 06 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 07 2017
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: October, 31 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 30 2017
Free Writing Prospectus
Filing Type: FWPFiling Source: edgar
Filing Date: October, 30 2017

 

 


Daily Technical Chart for (OTC: PSTI)

Daily Technical Chart for (OTC: PSTI)


Stay tuned for daily updates and more on (OTC: PSTI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PSTI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PSTI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of PSTI and does not buy, sell, or trade any shares of PSTI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/